Valuation, investor perception and Willow’s (TSX: WLLW) market opportunity as it closes in on the production of commercial quantities of pharma grade CBD and rare cannabinoids were amongst a variety of topics covered in a recent conversation between Grant Howard, President of The Howard Group, Trevor Peters, President & CEO and David Kideckel, Analyst, Managing Director of Healthcare and Life Sciences, ATB Capital Markets.
David Kideckel has a $2.75 target on Willow’s stock, which at the time of this writing is trading in a range of $0.45 to $0.55.
Segment one topics:
- The market should not be categorizing Willow as a cannabis company solely because its initial focus is the production of CBD and rare cannabinoids.
- Turbulence in the cannabis sector has created an opportunity for investors who appreciate Willow’s focus.
- The opportunities are immense within the consumer packaged goods sector and meeting the needs of pharma companies focused on drug development.
Segment two topics: (starts at 11:49)
- Why is Willow trading at a deep discount to David Kideckel’s target price?
What are the catalysts that will motivate the market to see the investment opportunity?
Segment three topic: (starts at 20:09)
- The opportunities – consumer packaged goods and pharma.
Segment One:
Segment Two:
Segment Three:
FULL DISCLOSURE: Willow Biosciences is a client of Stockhouse Publishing.